I-CAR T-Cell Therapy ETurkey

NGOBA-Ukwelashwa kwe-T iwuhlobo olusha lokwelapha umdlavuza olusebenzisa amasosha omzimba ukuqeda amangqamuzana omdlavuza. Lapho ezinye izindlela zokwelapha ziye zahluleka khona, ngezinye izikhathi liye lakwazi ukwelapha iziguli. Le bhulogi izogqamisa konke odinga ukukwazi mayelana nale nqubo. Qhubeka ufunde ukuze uthole okwengeziwe!

Yini i-CAR-T Cell therapy?

Lolu hlobo lokwelapha lubandakanya ukulungisa ama-T cell esiguli, uhlobo lwamangqamuzana omzimba omzimba, elebhu ukuze abophe futhi abulale amangqamuzana omdlavuza. Ishubhu lithutha igazi lisuka emthanjeni osengalweni yesiguli liye emshinini obizwa ngokuthi i-apheresis (ongabonisiwe), okhipha amangqamuzana amhlophe egazi, kuhlanganise nama-T cell, bese ubuyisela igazi elisele esigulini. 

Amaseli e-T abe eseshintshwa ngofuzo elebhu ukuze aqukathe ufuzo lwesamukeli esiyingqayizivele eyaziwa ngokuthi i-chimeric antigen receptor (CAR). Amaseli e-CAR T aphindaphindeka elebhu ngaphambi kokuthi afakwe esigulini ngamanani amakhulu. I-antigen emangqamuzaneni omdlavuza ingabonwa ngamaseli e-CAR T, abese ebulala amangqamuzana omdlavuza.

Ithini inqubo yokwelashwa kwamaseli e-CAR-T?

Inqubo yokwelapha i-CAR-T, ethatha amasonto ambalwa, ibandakanya izinyathelo eziningi:

Ama-T cell akhishwa egazini lakho kusetshenziswa ishubhu elifakwa emthanjeni wengalo. Lokhu kuthatha amahora ambalwa.

Ama-T cell athuthelwa endaweni lapho enza khona ukuguqulwa kofuzo ukuze abe amaseli e-CAR-T. Kudlula amasonto amabili kuya kwamathathu kukho konke lokhu.

Amangqamuzana e-CAR-T abuyiselwa egazini lakho nge-drip. Lokhu kudinga amahora ambalwa.

Amaseli e-CAR-T aqondisa futhi aqede amangqamuzana omdlavuza kuwo wonke umzimba. Ngemva kokuthola ukwelashwa kwe-CAR-T, uzobhekwa eduze.

Iyini imiphumela emibi yokwelashwa kwe-CAR-T Cell?

I-Cytokine release syndrome, noma i-CRS, iwumphumela ovamile we-CAR T-cell side. Elinye igama laso “yisiphepho se-cytokine.” Itholakala cishe ku-70-90% weziguli, kodwa ihlala izinsuku ezinhlanu kuya kweziyisikhombisa kuphela. Iningi labantu likuqhathanisa nokuba nomkhuhlane omubi, ogcwele umkhuhlane, ukukhathala kanye nobuhlungu bomzimba. 

Usuku lwesibili noma lwesithathu olulandela ukumnika ngokuvamile lapho luqala. Kwenzeka ngenxa yesimiso somzimba sokuzivikela ezifweni esisabela ekwandeni kwama-T cell kanye nokuhlasela kwesifo esiyingozi.

I-CRES, emele i-CAR T-cell-related encephalopathy syndrome, ingomunye umthelela omubi. Cishe ngosuku lwesihlanu kulandela ukumnika, kuvame ukuqala. Iziguli zingase zibe nokudideka nokudideka, futhi ngezinye izikhathi zingase zingakwazi ukukhuluma izinsuku ezimbalwa. 

Nakuba i-CRES ibuyiseleka emuva futhi ivame ukuhlala phakathi kwezinsuku ezimbili nezine, ingabacindezela iziguli nemindeni yazo. Yonke imisebenzi yezinzwa kancane kancane ibuyela kokujwayelekile ezigulini.

Hlobo luni lwamaseli omdlavuza olungelashwa nge-CAR-T Cell Therapy? 

Iziguli kuphela ezine-B-cell non-lymphoma Hodgkin's noma i-acute lymphoblastic leukemia yezingane esezizame ezimbili ezijwayelekile ezingaphumelelanga. zokwelapha okwamanje zingasebenzisa i-CAR T-cell imikhiqizo yokwelapha ethole imvume ye-FDA. Kodwa-ke, ukwelashwa kwe-CAR T-cell manje kuyahlolwa ezifundweni zomtholampilo njengokwelashwa komugqa wokuqala noma wesibili we-lymphoma yabantu abadala kanye nezingane. i-leukemia enamandla ye-lymphoblastic.

Yiziphi izinzuzo ze-CAR-T Cell therapy?

Inzuzo eyinhloko ukuthi ukwelashwa kwe-CAR T-cell kudinga kuphela ukumnika okukodwa futhi ngokuvamile kudinga kuphela amasonto amabili okunakekelwa kwesiguli. Iziguli nge i-non-Hodgkin lymphoma kanye ne-leukemia yezingane ezisanda kutholwa, ngakolunye uhlangothi, ngokuvamile zidinga ukwelashwa ngamakhemikhali okungenani izinyanga eziyisithupha noma ngaphezulu.

Izinzuzo zokwelashwa kwe-CAR T-cell, empeleni okuwumuthi ophilayo, zingaphikelela iminyaka eminingi. Uma futhi kwenzeka ukuphindeka, amaseli asazokwazi ukukhomba futhi aqondise amaseli omdlavuza ngoba angaphila emzimbeni isikhathi eside. 

Nakuba ulwazi lusathuthuka, u-42% wabantu abadala i-lymphoma iziguli ezathola ukwelashwa kwe-CD19 CAR T-cell zazisengcono ngemva kwezinyanga eziyi-15. Futhi ngemva kwezinyanga eziyisithupha, izingxenye ezimbili kwezintathu zeziguli ezine-acute lymphoblastic leukemia zazisaxole. Ngeshwa, lezi ziguli zinezimila ezinolaka kakhulu ezingazange zilashwe ngempumelelo kusetshenziswa izindinganiso zendabuko zokunakekela.

Hlobo luni lweziguli ezingaba ngabamukeli abahle be-CAR-T Cell Therapy?

Umuntu ongcono kakhulu wokwelashwa kwe-CAR T-cell ngalesi sikhathi yingane ene-acute lymphoblastic leukemia noma umuntu omdala one-B-cell lymphoma enamandla osevele enemigqa emibili yokwelapha okungasebenzi. 

Ngaphambi kokuphela kuka-2017, lalingekho izinga elamukelekayo lokunakekela ezigulini esezidlule emigqeni emibili yokwelashwa ngaphandle kokuthola ukuxolelwa. Okuwukuphela kwendlela yokwelapha egunyazwe i-FDA kuze kube manje osekufakazele ukuthi kunenzuzo enkulu kulezi ziguli ukwelapha nge-CAR T-cell.

Iyini ububanzi bokwelashwa kwe-CAR-T Cell eTurkey?

Umshayeli wendiza isivivinyo somtholampilo (I-NCT04206943) eklanyelwe ukuhlola ukuphepha nokusebenza kokwelashwa kwe-ISIKOK-19 T-cell ezigulini ezinamaqhubu aphinde abuyela emuva futhi ane-CD19+ ehlanekezelwe futhi iziguli ezibambe iqhaza zithole ukufakwa kwe-ISIKOK-19 phakathi kuka-Okthoba 2019 noJulayi 2021. Idatha yokukhiqiza yeziguli eziyi-8 zokuqala kanye nomphumela womtholampilo weziguli ezingu-7 ezithole i-ISIKOK-19 cell infusion uvezwa kulolu cwaningo.

Ezenye: Iziguli eziyisishiyagalolunye zibhaliselwe ukuhlola (ZONKE n=5 kanye ne-NHL n=4) kodwa yiziguli eziyi-7 kuphela ezingathola ukwelashwa. Iziguli ezimbili kwezintathu ZONKE kanye neziguli ezintathu kwezine ze-NHL zinempendulo ephelele/ingxenye (ORR 72%). Iziguli ezine (57%) zazinobuthi obuhlobene ne-CAR-T (CRS, CRES, ne-pancytopenia). Iziguli ezimbili zazingaphenduli futhi zazinesifo esiqhubekayo ngemva kokwelashwa kwe-CAR-T. Iziguli ezimbili ezinokusabela okuyingxenye zaba nesifo esiqhubekayo phakathi
Landelela.

Isiphetho: Ukusebenza kahle kokukhiqiza kanye nokufeza imibandela yokulawulwa kwekhwalithi bekugculisa ekukhiqizeni kwezemfundo. Amazinga okuphendula kanye namaphrofayili anobuthi ayamukeleka kuleli qembu lesiguli esilashwe kakhulu/esiphikayo. Amaseli e-ISIKOK-19 abonakala eyindlela yokwelapha ephephile, eyongayo, futhi ephumelelayo yamathumba ane-CD19 positive. Okutholwe kulolu cwaningo kufanele kube
kusekelwa uhlolo lomtholampilo oluqhubekayo lwe-ISIKOK-19.

Ukuphetha

Lokhu kubonisa intuthuko enkulu ekulawuleni i-leukemia kanye ne-B-cell lymphoma. Ukwengeza, kunikeza ithemba kulabo okwabikezelwa ukuthi ukuphila kwabo kuzohlala izinyanga eziyisithupha kuphela. Manje njengoba sesihlonze izindlela zokumelana futhi sakha amasu amaningi okulwa nazo, ikusasa libonakala lithembisa kakhulu.

Ukuze uthole imininingwane eyengeziwe nge-CAR-T Cell Therapy eTurkey, yiya kwethi iwebhusayithi. Xhumana nabahlinzeki bethu bokunakekelwa kwezempilo abanolwazi olunzulu lapha kwaCancerFax ukuze uthole ukubonisana mahhala ukuze wenze uhlelo lokunakekela olufanele lwezidingo zakho zezempilo!

Isithombe: Esinye sesibhedlela eTurkey lapho ukuhlolwa kwe-CAR T Cell kwenziwa khona.